Additionally, we found that PIK3CA mutations were present in about one-third of MKShi/ERSlo tumours, indicating a potential therapeutic option with PI3Kα-specific inhibitors such as alpelisib in this subgroup. This evidence concerns the gene PIK3CA and neoplasm.